BUSINESS

• Nippon Chemiphar to Boost Generic Production to 2 Billion Tablets by FY2018: President
  July 11, 2016

• NTD Collaboration with Astellas Began by Coincidence: Merck Global Health R&D Chief
  July 11, 2016

• Adcetris Approved for Add’l Indication in Europe: Takeda
  July 8, 2016

• Pfizer Adjusting Shipments of Certain Olanzapine Generics Due to Shortage
  July 8, 2016

• Heptares Earns US$10 Million Milestone on 1st Dosing of Immuno-Oncology Candidate
  July 7, 2016

• Parkinson’s Drug Opicapone Approved in Europe: Ono
  July 7, 2016

• AnGes MG Reports Disappointing Data for Nucleic Acid Drug, Filing Plan Now Back on Drawing Board
  July 7, 2016

• Kyorin Anticipates Annual Growth of “at Least 3%” through New Drugs Despite Patent Loss for Kipres: President
  July 7, 2016

• Oncolys, Nagoya Univ. to Jointly Research Combo Therapy of OBP-301, Checkpoint Inhibitor
  July 6, 2016

• Taisho Acquires 24.5% Stake in Vietnamese Drug Maker
  July 6, 2016

• Nippon Kayaku’s Novel DDS Formulation of Paclitaxel Disappoints in PIII for Breast Cancer
  July 6, 2016

• Takeda Gains Rights to TiGenix’s Cx601 Stem Cell Treatment Outside US
  July 6, 2016

• Delving into Securities Filings - 3: Six Companies Report Higher Pay, More Employees
  July 6, 2016

• Delving into Securities Filings - 2: Average Annual Pay at 3 Generic Majors Tops 7 Mil. Yen
  July 5, 2016

• Takeda Gets Option to Acquire US Developer of Gastroparesis Treatment
  July 5, 2016

• Takeda Files for Japan Approval of MM Drug Ixazomib
  July 5, 2016

• Belsomra Comes Back to Top Position in GP Market: Anterio
  July 4, 2016

• Delving into Securities Filings - 1: 1st and 2nd-Tier Makers Continue to Shed Jobs as Generic Peers See Rise in Workforce
  July 4, 2016

• Sanofi Japan Completes Merger of Genzyme Japan
  July 4, 2016

• Eisai Gives Global R&D Updates on Dementia, Oncology
  July 1, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 453
• 454
• 455
• 456
• 457
• 458
• 459
• 460
• 461
• …
• Next ›
• 最終 »